HIV-associated neurocognitive disorders

Howard S Fox, Phillip Purnell

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

HIV infection in the central nervous system (CNS) is responsible for a spectrum of neurocognitive and behavioral disorders. The wide use of appropriate combination antiretroviral therapy (cART) has decreased the severity of cognitive dysfunction. Viral loads are reduced and CD4+ T cell counts are increased. In addition, patients are living longer with improved quality of life. However, cART does not completely eliminate CNS dysfunction in HIV infected patients. There is an increase in milder forms of HIV-associated neurocognitive disorders (HAND), which are the result of a complex interplay between many factors including: aging, vascular disease, Alzheimer’s disease, and psychiatric disease. The underlying biochemical and molecular changes that underlie these changes and the underlying mechanisms of HAND pathogenesis continue to be an area of ongoing research. New advances in imaging and biomarker discovery will continue to advance clinical diagnosis and management. Treatments that can perturb the viral reservoirs and decrease chronic inflammatory response, in addition to continuing cART, may give the clinician additional tools to prevent HAND.

Original languageEnglish (US)
Title of host publicationNeuroimmune Pharmacology
PublisherSpringer International Publishing
Pages407-420
Number of pages14
ISBN (Electronic)9783319440224
ISBN (Print)9783319440200
DOIs
StatePublished - Jan 1 2016

Fingerprint

HIV
Central Nervous System
Therapeutics
CD4 Lymphocyte Count
Viral Load
Vascular Diseases
HIV Infections
Psychiatry
Alzheimer Disease
Biomarkers
Quality of Life
T-Lymphocytes
Neurocognitive Disorders
Research
Cognitive Dysfunction

Keywords

  • HIV pathogenesis
  • HIV-associated neurocognitive dysfunction (HAND)
  • cART

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fox, H. S., & Purnell, P. (2016). HIV-associated neurocognitive disorders. In Neuroimmune Pharmacology (pp. 407-420). Springer International Publishing. https://doi.org/10.1007/978-3-319-44022-4_27

HIV-associated neurocognitive disorders. / Fox, Howard S; Purnell, Phillip.

Neuroimmune Pharmacology. Springer International Publishing, 2016. p. 407-420.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fox, HS & Purnell, P 2016, HIV-associated neurocognitive disorders. in Neuroimmune Pharmacology. Springer International Publishing, pp. 407-420. https://doi.org/10.1007/978-3-319-44022-4_27
Fox HS, Purnell P. HIV-associated neurocognitive disorders. In Neuroimmune Pharmacology. Springer International Publishing. 2016. p. 407-420 https://doi.org/10.1007/978-3-319-44022-4_27
Fox, Howard S ; Purnell, Phillip. / HIV-associated neurocognitive disorders. Neuroimmune Pharmacology. Springer International Publishing, 2016. pp. 407-420
@inbook{265ffafe1c364f8d90d4fb7633b037f4,
title = "HIV-associated neurocognitive disorders",
abstract = "HIV infection in the central nervous system (CNS) is responsible for a spectrum of neurocognitive and behavioral disorders. The wide use of appropriate combination antiretroviral therapy (cART) has decreased the severity of cognitive dysfunction. Viral loads are reduced and CD4+ T cell counts are increased. In addition, patients are living longer with improved quality of life. However, cART does not completely eliminate CNS dysfunction in HIV infected patients. There is an increase in milder forms of HIV-associated neurocognitive disorders (HAND), which are the result of a complex interplay between many factors including: aging, vascular disease, Alzheimer’s disease, and psychiatric disease. The underlying biochemical and molecular changes that underlie these changes and the underlying mechanisms of HAND pathogenesis continue to be an area of ongoing research. New advances in imaging and biomarker discovery will continue to advance clinical diagnosis and management. Treatments that can perturb the viral reservoirs and decrease chronic inflammatory response, in addition to continuing cART, may give the clinician additional tools to prevent HAND.",
keywords = "HIV pathogenesis, HIV-associated neurocognitive dysfunction (HAND), cART",
author = "Fox, {Howard S} and Phillip Purnell",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-44022-4_27",
language = "English (US)",
isbn = "9783319440200",
pages = "407--420",
booktitle = "Neuroimmune Pharmacology",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - HIV-associated neurocognitive disorders

AU - Fox, Howard S

AU - Purnell, Phillip

PY - 2016/1/1

Y1 - 2016/1/1

N2 - HIV infection in the central nervous system (CNS) is responsible for a spectrum of neurocognitive and behavioral disorders. The wide use of appropriate combination antiretroviral therapy (cART) has decreased the severity of cognitive dysfunction. Viral loads are reduced and CD4+ T cell counts are increased. In addition, patients are living longer with improved quality of life. However, cART does not completely eliminate CNS dysfunction in HIV infected patients. There is an increase in milder forms of HIV-associated neurocognitive disorders (HAND), which are the result of a complex interplay between many factors including: aging, vascular disease, Alzheimer’s disease, and psychiatric disease. The underlying biochemical and molecular changes that underlie these changes and the underlying mechanisms of HAND pathogenesis continue to be an area of ongoing research. New advances in imaging and biomarker discovery will continue to advance clinical diagnosis and management. Treatments that can perturb the viral reservoirs and decrease chronic inflammatory response, in addition to continuing cART, may give the clinician additional tools to prevent HAND.

AB - HIV infection in the central nervous system (CNS) is responsible for a spectrum of neurocognitive and behavioral disorders. The wide use of appropriate combination antiretroviral therapy (cART) has decreased the severity of cognitive dysfunction. Viral loads are reduced and CD4+ T cell counts are increased. In addition, patients are living longer with improved quality of life. However, cART does not completely eliminate CNS dysfunction in HIV infected patients. There is an increase in milder forms of HIV-associated neurocognitive disorders (HAND), which are the result of a complex interplay between many factors including: aging, vascular disease, Alzheimer’s disease, and psychiatric disease. The underlying biochemical and molecular changes that underlie these changes and the underlying mechanisms of HAND pathogenesis continue to be an area of ongoing research. New advances in imaging and biomarker discovery will continue to advance clinical diagnosis and management. Treatments that can perturb the viral reservoirs and decrease chronic inflammatory response, in addition to continuing cART, may give the clinician additional tools to prevent HAND.

KW - HIV pathogenesis

KW - HIV-associated neurocognitive dysfunction (HAND)

KW - cART

UR - http://www.scopus.com/inward/record.url?scp=85045997951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045997951&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-44022-4_27

DO - 10.1007/978-3-319-44022-4_27

M3 - Chapter

AN - SCOPUS:85045997951

SN - 9783319440200

SP - 407

EP - 420

BT - Neuroimmune Pharmacology

PB - Springer International Publishing

ER -